SCHEMBL5887214

SCHEMBL5887214

COc1ccc(C2=C(c3ccc(Cl)c(Cl)c3)C[CH]C(Cl)=C2Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAD51 Q06609 2/20 0.46
ALKBH3 Q96Q83 1/20 0.39
RAD1 O60671 1/20 0.38
SLC6A2 P23975 4/20 0.37
SLC6A3 Q01959 4/20 0.37
EGFR P00533 2/20 0.37
GUSB P08236 1/20 0.37
EDNRB P24530 1/20 0.36
EDNRA P25101 1/20 0.36
TEK Q02763 1/20 0.36
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35
MAPK10 P53779 1/20 0.35
AHR P35869 1/20 0.35
ESR1 P03372 1/20 0.35
BCL2A1 Q16548 1/20 0.35
SRC P12931 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887087 0.81 RAD51 (0.41) RAD51ALKBH3RAD1SLC6A2SLC6A3
SCHEMBL5887265 0.80 LTA4H (0.49) ESR1
SCHEMBL5887629 0.78 ALKBH3 (0.46) ALKBH3SLC6A3EGFRAHRESR1
SCHEMBL5887168 0.77 RAD51 (0.39) RAD51RAD1SLC6A2SLC6A3EGFR
SCHEMBL2092168 0.73 AHR (0.61) RAD51GUSBTEKAHR
SCHEMBL5886940 0.69 RAD51 (0.40) RAD51ALKBH3RAD1EGFRGUSB
SCHEMBL5887406 0.68 PTGS1 (0.42) ESR1
SCHEMBL5887298 0.67 RAD51 (0.40) RAD51ALKBH3RAD1EGFRGUSB
SCHEMBL5887361 0.66 RAD51 (0.40) RAD51ALKBH3RAD1EGFRGUSB
SCHEMBL29768449 0.65 SLC6A4 (0.54) SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R RAD51 2282/4885ALKBH3 3753/4885RAD1 2432/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R RAD51 1217/4885ALKBH3 3208/4885RAD1 1222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.